{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T20:12:10Z","timestamp":1791403930838,"version":"4.3.3"},"reference-count":36,"publisher":"Elsevier BV","issue":"1-3","license":[{"start":{"date-parts":[[2008,9,1]],"date-time":"2008-09-01T00:00:00Z","timestamp":1220227200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European Journal of Pharmacology"],"published-print":{"date-parts":[[2008,9]]},"DOI":"10.1016\/j.ejphar.2008.06.100","type":"journal-article","created":{"date-parts":[[2008,7,7]],"date-time":"2008-07-07T19:34:11Z","timestamp":1215459251000},"page":"103-108","source":"Crossref","is-referenced-by-count":41,"title":["Aripiprazole inhibits marble-burying behavior via 5-hydroxytryptamine (5-HT)1A receptor-independent mechanisms"],"prefix":"10.1016","volume":"592","author":[{"given":"Nobuaki","family":"Egashira","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryoko","family":"Okuno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michihiko","family":"Matsushita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moe","family":"Abe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenichi","family":"Mishima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katsunori","family":"Iwasaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryoji","family":"Nishimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryozo","family":"Oishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michihiro","family":"Fujiwara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejphar.2008.06.100_bib1","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1038\/sj.npp.1300940","article-title":"Antipsychotic-like vs cataleptogenic actions in mice of novel antipsychotics having D2 antagonist and 5-HT1A agonist properties","volume":"31","author":"Bardin","year":"2006","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.ejphar.2008.06.100_bib2","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1016\/S0028-3908(96)00110-4","article-title":"5-HT1A receptors are not involved in clozapine's lack of cataleptogenic potential","volume":"35","author":"Bartoszyk","year":"1996","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.ejphar.2008.06.100_bib3","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1038\/sj.mp.4001823","article-title":"A systematic review: antipsychotic augmentation with treatment refractory obsessive\u2013compulsive disorder","volume":"11","author":"Bloch","year":"2006","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.ejphar.2008.06.100_bib4","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1007\/s00213-007-0698-y","article-title":"In vivo actions of aripiprazole on serotonergic and dopaminergic systems in rodent brain","volume":"191","author":"Bortolozzi","year":"2007","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.ejphar.2008.06.100_bib5","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1016\/S0028-3908(03)00113-8","article-title":"Evidence for regulation of body temperature in rats by dopamine D2 receptor and possible influence of D1 but not D3 and D4 receptors","volume":"44","author":"Chaperon","year":"2003","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.ejphar.2008.06.100_bib6","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.ejphar.2007.02.019","article-title":"Involvement of the sigma1 receptor in inhibiting activity of fluvoxamine on marble-burying behavior: comparison with paroxetine","volume":"563","author":"Egashira","year":"2007","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.ejphar.2008.06.100_bib7","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1007\/s00213-003-1611-y","article-title":"Anandamide inhibits the DOI-induced head-twitch response in mice","volume":"171","author":"Egashira","year":"2004","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.ejphar.2008.06.100_bib8","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.neulet.2003.11.050","article-title":"V1a receptor knockout mice exhibit impairment of spatial memory in an eight-arm radial maze","volume":"356","author":"Egashira","year":"2004","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.ejphar.2008.06.100_bib9","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1001\/archpsyc.1989.01810010038006","article-title":"Efficacy of fluvoxamine in obsessive\u2013compulsive disorder. A double-blind comparison with placebo","volume":"46","author":"Goodman","year":"1989","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.ejphar.2008.06.100_bib10","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1017\/S1092852900006908","article-title":"WCA recommendations for the long-term treatment of obsessive\u2013compulsive disorder in adults","volume":"8","author":"Greist","year":"2003","journal-title":"CNS. Spectr."},{"key":"10.1016\/j.ejphar.2008.06.100_bib11","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1097\/01.fbp.0000236266.34182.1c","article-title":"Role of serotonin type 1A receptors in fluvoxamine-induced inhibition of marble-burying behavior in mice","volume":"17","author":"Harasawa","year":"2006","journal-title":"Behav. Pharmacol."},{"key":"10.1016\/j.ejphar.2008.06.100_bib12","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1038\/sj.bjp.0706108","article-title":"Relationship between brain serotonin transporter binding, plasma concentration and behavioural effect of selective serotonin reuptake inhibitors","volume":"144","author":"Hirano","year":"2005","journal-title":"Brit. J. Pharmacol."},{"issue":".","key":"10.1016\/j.ejphar.2008.06.100_bib13","doi-asserted-by":"crossref","first-page":"284","DOI":"10.2152\/jmi.52.284","article-title":"Aripiprazole, a novel antipsychotic agent: dopamine D2 receptor partial agonist","volume":"52","author":"Hirose","year":"2005","journal-title":"J. Med. Invest"},{"key":"10.1016\/j.ejphar.2008.06.100_bib14","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1017\/S1461145703003730","article-title":"Risperidone augmentation in treatment-resistant obsessive\u2013compulsive disorder: a double-blind, placebo-controlled study","volume":"6","author":"Hollander","year":"2003","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.ejphar.2008.06.100_bib15","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1254\/jjp.68.65","article-title":"5-HT1A-receptor subtype mediates the effect of fluvoxamine, a selective serotonin reuptake inhibitor, on marble-burying behavior in mice","volume":"68","author":"Ichimaru","year":"1995","journal-title":"Jpn. J. Pharmacol."},{"issue":"441","key":"10.1016\/j.ejphar.2008.06.100_bib16","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/S0014-2999(02)01532-7","article-title":"The antipsychotic aripiprazole is a potent, partial agonist at the human 5-HT1A receptor","volume":"26","author":"Jordan","year":"2002","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.ejphar.2008.06.100_bib17","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.neuropharm.2005.02.005","article-title":"Novel antipsychotic agents with 5-HT1A agonist properties: role of 5-HT1A receptor activation in attenuation of catalepsy induction in rats","volume":"49","author":"Kleven","year":"2005","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.ejphar.2008.06.100_bib18","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.ejphar.2004.04.028","article-title":"Aripiprazole, a novel antipsychotic drug, preferentially increases dopamine release in the prefrontal cortex and hippocampus in rat brain","volume":"493","author":"Li","year":"2004","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.ejphar.2008.06.100_bib19","doi-asserted-by":"crossref","first-page":"251","DOI":"10.2165\/00023210-200418040-00005","article-title":"Dopamine partial agonists: a new class of antipsychotic","volume":"18","author":"Lieberman","year":"2004","journal-title":"CNS Drugs"},{"key":"10.1016\/j.ejphar.2008.06.100_bib20","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/S0166-4328(97)00162-9","article-title":"Investigative burying by laboratory mice may involve non-functional, compulsive, behaviour","volume":"94","author":"Londei","year":"1998","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.ejphar.2008.06.100_bib21","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.biopsych.2007.01.014","article-title":"Prenatal exposure to cocaine increases the rewarding potency of cocaine and selective dopaminergic agonists in adult mice","volume":"63","author":"Malanga","year":"2008","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.ejphar.2008.06.100_bib22","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1254\/jphs.FP0050144","article-title":"Perospirone, a novel antipsychotic drugs, inhibits marble-burying behavior via 5-HT1A receptor in mice: implications for obsessive\u2013compulsive disorder","volume":"99","author":"Matsushita","year":"2005","journal-title":"J. Pharmacol. Sci."},{"key":"10.1016\/j.ejphar.2008.06.100_bib23","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1016\/j.pnpbp.2004.06.020","article-title":"Aripiprazole: a new atypical antipsychotic with a different pharmacological mechanism","volume":"28","author":"Naber","year":"2004","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.ejphar.2008.06.100_bib24","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/j.pbb.2006.05.018","article-title":"Antipsychotics improve \u03949-tetrahydrocannabinol-induced impairment of the prepulse inhibition of the startle reflex in mice","volume":"84","author":"Nagai","year":"2006","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.ejphar.2008.06.100_bib25","first-page":"207","article-title":"Serotonergic involvement in haloperidol-induced catalepsy","volume":"265","author":"Neal-Beliveau","year":"1993","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.ejphar.2008.06.100_bib26","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0014-2999(98)00982-0","article-title":"Preferential inhibition of dizocilpine-induced hyperlocomotion by olanzapine","volume":"368","author":"Ninan","year":"1999","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.ejphar.2008.06.100_bib27","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/0091-3057(91)90590-X","article-title":"Evaluation of marble-burying behavior as a model of anxiety","volume":"38","author":"Njung ' e","year":"1991","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.ejphar.2008.06.100_bib28","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1111\/j.1476-5381.1991.tb12392.x","article-title":"Effects of 5-HT uptake inhibitors, agonists and antagonists on the burying of harmless objects by mice; a putative test for anxiolytic agents","volume":"104","author":"Njung'e","year":"1991","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.ejphar.2008.06.100_bib29","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/S0014-2999(02)02430-5","article-title":"5-HT1A receptor activation and anti-cataleptic effects: high-efficacy agonists maximally inhibit haloperidol-induced catalepsy","volume":"453","author":"Prinssen","year":"2002","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.ejphar.2008.06.100_bib30","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1007\/s002130050972","article-title":"Interactions between neuroleptics and 5-HT1A ligands in preclinical behavioral models for antipsychotic and extrapyramidal effects","volume":"144","author":"Prinssen","year":"1999","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.ejphar.2008.06.100_bib31","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/S0193-953X(18)30205-3","article-title":"The epidemiology and clinical features of obsessive\u2013compulsive disorder","volume":"15","author":"Rasmussen","year":"1992","journal-title":"Psychiatr. Clin. North Am."},{"key":"10.1016\/j.ejphar.2008.06.100_bib32","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1016\/j.pnpbp.2007.07.008","article-title":"Successful augmentation with aripiprazole in clomipramine-refractory obsessive\u2013compulsive disorder","volume":"31","author":"da Rocha","year":"2007","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.ejphar.2008.06.100_bib33","first-page":"7","article-title":"Epidemiology of obsessive\u2013compulsive disorder: a world view","volume":"58","author":"Sasson","year":"1997","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.ejphar.2008.06.100_bib34","first-page":"685","article-title":"Effect of paroxetine on marble-burying behavior in mice. Methods Find","volume":"27","author":"Shinomiya","year":"2005","journal-title":"Exp. Clin. Pharmacol."},{"key":"10.1016\/j.ejphar.2008.06.100_bib35","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1007\/s00213-004-1866-y","article-title":"Combined treatment of quetiapine with haloperidol in animal models of antipsychotic effect and extrapyramidal side effects: comparison with risperidone and chlorpromazine","volume":"176","author":"Tada","year":"2004","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.ejphar.2008.06.100_bib36","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/0091-3057(94)90152-X","article-title":"Evidence for specific interactions between 5-HT1A and dopamine D2 receptor mechanisms in the mediation of extrapyramidal motor functions in the rat","volume":"47","author":"Wadenberg","year":"1994","journal-title":"Pharmacol. Biochem. Behav."}],"container-title":["European Journal of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299908007103?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299908007103?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,5,12]],"date-time":"2019-05-12T14:08:16Z","timestamp":1557670096000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014299908007103"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,9]]},"references-count":36,"journal-issue":{"issue":"1-3","published-print":{"date-parts":[[2008,9]]}},"alternative-id":["S0014299908007103"],"URL":"https:\/\/doi.org\/10.1016\/j.ejphar.2008.06.100","relation":{},"ISSN":["0014-2999"],"issn-type":[{"value":"0014-2999","type":"print"}],"subject":[],"published":{"date-parts":[[2008,9]]}}}